Given that BACE1 has several endogenous substrates other than APP and that mice with loss of BACE1 activity present abnormal behavior (36, –, 38) and axonal disorganization (39), a partial suppression of BACE1 activity is desirable for long-term therapeutic agents in AD. This evidence concerns the gene APP and Alzheimer disease.